MUSCLE SPASM IMPACTS ~84% OF U.S. ADULTS
Awaken to the possibility of relief
First Patient Enrolled in Phase 3, RESUME-1
Neurana Pharmaceuticals is developing a novel, non-opioid, non-drowsy,
non-cognitive impairing treatment for acute and painful muscle spasms
NEURANA -
Bringing new treatment options for muscle spasms
Neurana’s lead product, tolperisone, has a pharmacological profile that may offer unique benefits to patients suffering from muscle spasms
Put your cursor over years in the timeline to see the history of muscle spasm treatment options
TOLPERISONE U.S. CLINICAL STUDIES
UNDERWAY/
PLANNED
COMPLETED
TEAM
Visionary management and investors committed to reducing the pain and disability that can accompany acute muscle spasms
